Company intelligence / Profile preview

Alios BioPharma

South San Francisco, California, United Statesjnj.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Alios BioPharma developed AL-8176, an orally administered antiviral therapy for RSV that showed promising results in Phase 2 studies. In clinical trials, volunteers infected with RSV showed no symptoms within a day and a half of receiving the drug and completely lost the virus, while the placebo group had persistent virus and symptoms for several days.

Therapeutic areas: Infectious Diseases
Modalities: Nucleoside analogsAntiviral therapeutics
Industry: Biotech

Drug pipeline

4 assets

AL-8176

Phase 2

Indications: Respiratory syncytial virus infection

3 more assets in the full pipeline.

Request access →

Partnerships

Vertex PharmaceuticalsJanssen Pharmaceutical Companies of Johnson & Johnson

Beyond the preview

Go deeper on Alios BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alios BioPharma.

Explore the full profile